utritional Supplements for prevention of type 2 diabetes

Phase 3

Completed

• Conditions: Pre-diabetes; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12615000559516
• Lead Sponsor: niversity of Newcastle

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Age – 30-70; gender – both males and females
No participation in any clinical trial for at least 3 months
An HbA1c of 5.7% - 6.4%
Impaired Glucose Tolerance (IGT):
2-hour OGTT plasma glucose greater than or equal to 7.8 mmol/ Land <11.1 mmol/L
Impaired fasting glucose (IFG):
Fasting plasma venous glucose measurement 6.1–6.9 mmol/L
12 or more score or High risk individuals in AUSDRISK assessment tool
BMI between 25-45

Exclusion Criteria

Pregnancy or lactation
Established type 2 diabetes
Allergic to sea foods
People with gall bladder problems
People currently on medication with erythropoietin
People with anaemia
People with pace maker implants
Currently on medication with Aspirin and Warfarin
History of severe neurological diseases or seizures
History of new investigational drug three months prior to this trial
Consuming more than 2 serve of oily fish per week
Taking regular dietary supplements known to influence blood glucose level
People taking regular vitamin C supplements
Unwilling to fast for 10hr before obtaining blood samplePeople currently on medication with clopidogrel, ibuprofen, naproxen, dalteparin, enoxaparin and heparin,

Study & Design

• Study Type: Interventional
• Study Design: Not specified